洛铂联合方案治疗晚期乳腺癌的临床研究  

Clinical study of chemotherapy contains Lobaplatin in treating advanced breast cancer

作　　者：张娜[1] 刘美[1] 曾晓华[1] 辇伟奇[1] ZHANG Na L IU Mei ZENG Xiaohua NIAN Weiqi(Breast Care Center, Chongqing Cancer Hospital, Chongqing 400030, Chin)

机构地区：[1]重庆市肿瘤研究所乳腺中心,400030

出　　处：《检验医学与临床》2016年第19期2749-2751,2754,共4页Laboratory Medicine and Clinic

摘　　要：目的探讨洛铂联合化疗方案在治疗晚期乳腺癌中的疗效与不良反应。方法收集2012年1月至2014年12月共52例晚期乳腺癌患者,予以洛铂联合化疗方案治疗,21-28d为1个周期。所有患者至少完成2个周期治疗,之后评价疗效及不良反应。结果无1例达到完全缓解（CR）,部分缓解（PR）16例,疾病稳定（SD）21例,疾病进展（PD）15例,有效率（RR）为30.8%,疾病控制率（DCR）为71.2%。雌激素受体（ER）或人类表皮生长因子2（HER-2）阳性表达者与阴性表达者比较,RR差异均无统计学意义（P〉0.05）。一线治疗者与二线及以上治疗者比较,RR差异有统计学意义（P〈0.05）。三阴性乳腺癌患者中,乳腺癌易感基因1（BRCA1）突变者与BRCA1无突变者的DCR比较,差异有统计学意义（P〈0.05）。无内脏转移患者RR高于有内脏转移患者,差异有统计学意义（P〈0.05）。至随访日期止,46例患者为PD,中位疾病进展时间为6.5个月（95%置信区间为5.2-7.8个月）。主要不良反应为骨髓抑制、胃肠道反应等,多为0-Ⅱ度,经对症处理后可缓解,无治疗相关性死亡。结论洛铂联合化疗方案治疗晚期乳腺癌疗效较好,不良反应均可耐受。Objective To observe the efficacy and adverse reactions of chemotherapy regimens containing Lobaplatin in treatment of advanced breast cancer.Methods From January 2012 to December 2014,a total of 52 cases of advanced breast cancer were collected,who accepted Lobaplatin-containing chemotherapy regimens,21-28 days as a cycle.All patients completed at least two cycles and then the efficacy and adverse reactions were evaluated.Results No case obtained complete remission（CR）,16 patients achieved part remission（PR）,21 patients achieved stable disease（SD）,15 patients achieved disease progression（PD）.The response rate was 30.8%,and the disease control rate was 71.2%.There were no significant differences on the response rate among patients with negative and positive results of estrogen receptors（ER）and human epidermal growth factor receptor-2（HER-2）（P〈0.05）.The significant difference was found on RR between the first-line treatment and second-line treatment（P〈0.05）.Among triple negative breast cancer patients,Stratification analysis by BRCA1 status,there was significant difference of DCR between negative and positive BRCA1patients（P〈0.05）.The significant difference was found on RR between no visceral metastasis and visceral metastases patients（P〈0.05）.Follow-up to the deadline,the disease of 46 patients had progressed,the median time of progression was 6.5months（95% CI：5.2-7.8months）.The main side effects were myelosuppression,gastrointestinal reactions,which were mostly in degree 0- Ⅱ,and alleviated by symptomatic treatment.No treatment-related deaths occurred.Conclusion Lobaplatincontained regimens has a significant antitumor effect to advanced breast cancer with manageable toxicities.

关 键 词：乳腺癌 洛铂 联合化疗 

分 类 号：R979.1[医药卫生—药品]